Profile data is unavailable for this security.
About the company
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
- Revenue in JPY (TTM)269.49m
- Net income in JPY-763.75m
- Incorporated2007
- Employees44.00
- LocationStella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
- Phone+81 647071516
- Fax+81 647072077
- Websitehttps://stella-pharma.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wakamoto Pharmaceutical Co Ltd | 7.74bn | 108.96m | 8.57bn | 274.00 | 78.36 | 0.71 | 16.46 | 1.11 | 3.14 | 3.14 | 222.97 | 346.51 | 0.4971 | 2.09 | 2.57 | 28,242,430.00 | 0.70 | -2.28 | 0.8046 | -2.64 | 46.52 | 51.00 | 1.41 | -3.97 | 3.85 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| Solasia Pharma KK | 408.00m | -1.18bn | 8.91bn | 24.00 | -- | 4.10 | -- | 21.84 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| K Pharma Inc | 500.00m | -221.98m | 9.04bn | 15.00 | -- | 3.15 | -- | 18.08 | -18.94 | -18.94 | 43.04 | 247.43 | 0.2095 | 4.49 | -- | 33,333,330.00 | -9.30 | -- | -9.83 | -- | 91.00 | -- | -44.40 | -- | 42.60 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Perseus Proteomics Inc | 100.40m | -1.10bn | 10.08bn | 25.00 | -- | 5.84 | -- | 100.35 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | 4,016,080.00 | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Kohjin Bio Co Ltd | 4.77bn | 384.98m | 10.89bn | 159.00 | 23.08 | 3.20 | 15.90 | 2.28 | 92.30 | 92.30 | 1,122.07 | 666.48 | -- | -- | -- | 30,000,600.00 | -- | -- | -- | -- | 39.44 | -- | 8.07 | -- | 1.14 | -- | 0.4249 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 11.63bn | 12.00 | -- | 3.88 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Oncolys Biopharma Inc | 28.04m | -1.98bn | 12.47bn | 34.00 | -- | 6.88 | -- | 444.67 | -107.77 | -107.77 | 1.52 | 84.14 | 0.0127 | 0.00 | 0.1476 | 824,647.10 | -89.46 | -45.75 | -101.52 | -51.86 | 100.00 | 60.46 | -7,058.44 | -233.66 | 8.82 | -- | 0.1416 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| ReproCell Inc | 2.43bn | -31.42m | 12.85bn | 96.00 | -- | 1.48 | 2,254.74 | 5.29 | -0.3466 | -0.3466 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | 25,279,340.00 | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 13.91bn | 109.00 | -- | 1.94 | -- | 3.00 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 334.66bn | 2.21bn | 14.10bn | 632.00 | 6.24 | 0.491 | 5.63 | 0.0421 | 160.45 | 160.45 | 24,293.96 | 2,040.70 | 2.56 | 13.33 | 4.80 | 529,526,900.00 | 1.63 | 1.85 | 7.07 | 8.42 | 5.14 | 6.16 | 0.6356 | 0.7178 | 0.8922 | -- | 0.1996 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
| RaQualia Pharma Inc | 2.18bn | -253.40m | 14.22bn | 67.00 | -- | 2.37 | -- | 6.52 | -11.72 | -11.72 | 100.79 | 277.21 | 0.247 | 2.76 | 3.03 | 32,526,720.00 | -2.87 | 2.13 | -3.18 | 2.26 | 88.70 | 88.49 | -11.63 | 5.32 | 3.53 | -- | 0.4031 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Stella Pharma Corp | 269.49m | -763.75m | 14.24bn | 44.00 | -- | 5.50 | -- | 52.83 | -24.63 | -24.63 | 8.70 | 76.12 | 0.0661 | 0.0508 | 3.98 | 6,124,796.00 | -18.74 | -22.50 | -21.00 | -24.83 | 80.63 | -- | -283.40 | -488.65 | 5.52 | -1,319.97 | 0.2819 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| CellSeed Inc | 193.68m | -892.21m | 17.22bn | 35.00 | -- | 7.69 | -- | 88.92 | -29.71 | -29.71 | 6.47 | 64.75 | 0.088 | 1.63 | 7.62 | 5,533,600.00 | -40.53 | -49.69 | -43.83 | -54.55 | 56.58 | 63.66 | -460.67 | -428.62 | 19.14 | -- | 0.0669 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Fuso Pharmaceutical Industries Ltd | 55.41bn | 1.38bn | 21.16bn | 1.31k | 14.01 | 0.5219 | 5.91 | 0.3819 | 159.76 | 159.76 | 6,434.77 | 4,290.49 | 0.7474 | 3.12 | 2.43 | 42,392,500.00 | 1.86 | 1.91 | 3.06 | 3.09 | 24.98 | 26.92 | 2.49 | 2.69 | 1.04 | 54.56 | 0.2576 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
Data as of Jul 26 2024. Currency figures normalised to Stella Pharma Corp's reporting currency: Japanese Yen JPY
9.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 30 Dec 2022 | 2.84m | 8.83% |
| Simplex Asset Management Co., Ltd.as of 04 Jul 2024 | 105.00k | 0.33% |
Data from 30 Jun 2024 - 11 Jul 2024Source: FactSet Research Systems Inc.
